Dr. Wachman received her MD from the BU School of Medicine before pursuing her pediatric residency at Boston Medical Center (BMC) and Children’s Hospital Boston. She then completed her neonatology fellowship at the Floating Hospital for Children at Tufts Medical Center. She is currently an attending neonatologist at BMC and a leader in neonatal abstinence syndrome (NAS) quality improvement and research at BMC. Her research interests include the genetics and epigenetics of NAS, breastfeeding in the setting of maternal substance use disorders, and the use of non-pharmacologic care methods to improve NAS outcomes. She is the neonatal lead of the Massachusetts (MA) neoQIC NAS Quality Improvement Collaborative. She was a site investigator in a NIDA funded clinical trial comparing the short-term and long-term outcomes of methadone versus morphine for NAS and is currently the principal investigator of a NICHD funded study examining the safety, efficacy, pharmacokinetics, pharmacogenomics, and long-term maternal and infant outcomes of extended-release naltrexone for pregnant women with opioid use disorder.
- Boston University School of Medicine, MD
- Georgetown University, BS
- Published on 9/5/2019
Stulac S, Bair-Merritt M, Wachman EM, Augustyn M, Howard C, Madoor N, Costello E. Children and families of the opioid epidemic: Under the radar. Curr Probl Pediatr Adolesc Health Care. 2019 Sep 05; 100637. PMID: 31494050.
- Published on 8/19/2019
Minear S, Wachman EM. Management of Newborns with Prenatal Opioid Exposure: One Institution's Journey. Clin Ther. 2019 Aug 19. PMID: 31439335.
- Published on 7/27/2019
Wachman EM, Saia K, Miller M, Valle E, Shrestha H, Carter G, Werler M, Jones H. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects. Clin Ther. 2019 Jul 27. PMID: 31358302.
- Published on 7/24/2019
Wachman EM, Hunter RG, Shrestha H, Lapp HE, Meyer J, Alvarez CD, Tronick E. Maternal hair cortisol levels as a novel predictor of neonatal abstinence syndrome severity: A pilot feasibility study. Dev Psychobiol. 2019 Jul 24. PMID: 31342518.
- Published on 7/3/2019
Wachman EM, Minear S, Hirashima M, Hansbury A, Hutton E, Shrestha H, Combs G, Barry K, Slater C, Stickney D, Walley AY. Standard Fixed-Schedule Methadone Taper Versus Symptom-Triggered Methadone Approach for Treatment of Neonatal Opioid Withdrawal Syndrome. Hosp Pediatr. 2019 Aug; 9(8):576-584. PMID: 31270130.
- Published on 5/28/2019
Wachman EM. How Might Maternal Poverty Impact the Course of Neonatal Opioid Withdrawal Syndrome? J Addict Med. 2019 May 28. PMID: 31149916.
- Published on 3/1/2019
Wachman EM, Werler MM. Pharmacologic Treatment for Neonatal Abstinence Syndrome: Which Medication Is Best? JAMA Pediatr. 2019 Mar 01; 173(3):221-223. PMID: 30667482.
- Published on 3/1/2019
Jones HE, Kaltenbach K, Benjamin T, Wachman EM, O'Grady KE. Prenatal Opioid Exposure, Neonatal Abstinence Syndrome/Neonatal Opioid Withdrawal Syndrome, and Later Child Development Research: Shortcomings and Solutions. J Addict Med. 2019 Mar/Apr; 13(2):90-92. PMID: 30334926.
- Published on 1/25/2019
Wachman EM, Farrer LA. The genetics and epigenetics of Neonatal Abstinence Syndrome. Semin Fetal Neonatal Med. 2019 Apr; 24(2):105-110. PMID: 30709700.
- Published on 11/13/2018
Rose-Jacobs R, Trevino-Talbot M, Lloyd-Travaglini C, Cabral HJ, Vibbert M, Saia K, Wachman EM. Could prenatal food insecurity influence neonatal abstinence syndrome severity? Addiction. 2019 Feb; 114(2):337-343. PMID: 30422365.
View 25 more publications: View full profile at BUMC